News

By Giovanna Verginelli Mezher

2024-2025 Regulatory Agenda Has Been Approved by the Brazilian FDA

ANVISA’s new Regulatory Agenda 2024-2025 (RA 24/25) was approved and published on the Official Gazette on December 18th. The Joint Ordinance No. 1.409 of 2023 approved the Regulatory Agenda (RA) which covers the priorities for the 2024-2025 biennium.

The Regulatory Agenda is a planning instrument for the normative activities of the Agency. It presents several priority topics to be regulated by ANVISA whilst its validity. Therefore, such Agenda sheds light on the themes do to be improved by regulatory means for the next two years in Brazil.

Social participation alongside the National Sanitary Surveillance System (Sistema Nacional de Vigilância Sanitária – SNVS) was crucial to the construction of the RA 24/25. There were 1.449 contributions received by ANVISA’s Public Consultancy.

The just approved agenda covers 172 regulatory themes, divided into 16 macro themes. Topics that received most regulatory demands include Drugs with 45 themes, Food with 34 themes and cross-sectional issues with 23 themes. 

106 out of the 172 themes pertaining the new agenda are related to the subject matters already announced on the 2021-2023 agenda. 66 themes are new and unrelated to the previous agenda. 

The Regulatory Agenda 2024-2025 guarantees visibility and transparency for the normative regulatory activities by ANVISA. It will come into effect on January 2nd, 2024.

For more information regarding ANVISA, please do not hesitate to contact us by email: regulatorio@kasznarleonardos.com.

Back

Last by Giovanna Verginelli Mezher

July 2, 2024

Life Sciences’ Brazil Global Guide 2024 is now available

We are pleased to announce our collaboration on the Chambers and Partners Life Sciences 2024 Global Practice Guide! Our partners Priscila Kashiwabara Life Sciences’ Brazil Global Guide 2024 is now available

Ler notícia

May 29, 2024

New Regulation Approved by Anvisa Simplifies the Registration Process for Biosimilar Medicines

Anvisa approved the new simplified regulation for the registration of biosimilar medicines, whose publication in the Official Gazette (DOU) is still awaited. New Regulation Approved by Anvisa Simplifies the Registration Process for Biosimilar Medicines

Ler notícia

April 17, 2024

Anvisa opens its doors to Startups: Stepping towards Innovation in Medicines

Anvisa recently launched a public notice with the aim of selecting Startups involved in the research and development of medicines, in order Anvisa opens its doors to Startups: Stepping towards Innovation in Medicines

Ler notícia
plugins premium WordPress